Payment overview · 2025
General Payments
$4,528.15
258 reported records · 36 companies
Healthcare provider profile · identity verified
Randall S Williams, MD
Allopathic & Osteopathic Physicians|General Practice · CHICO, CA · NPI 1245261114
Verified facts
What the public records show
CMS Open Payments records show Randall S Williams, MD received $4,528.15 in general payments during 2025 across 258 reported records.
ABBVIE INC. accounted for 17.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 57 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Gemtesa, Jardiance, Linzess, Mounjaro, Ozempic, Paxlovid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 198 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 365 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 585 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 197 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 198 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $798.27 | 17.6% | 56 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $620.85 | 13.7% | 50 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $435.53 | 9.6% | 20 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $386.79 | 8.5% | 26 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $288.76 | 6.4% | 9 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $256.35 | 5.7% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $207.69 | 4.6% | 15 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $144.07 | 3.2% | 9 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $118.22 | 2.6% | 6 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $112.32 | 2.5% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $110.72 | 2.5% | 5 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $100.45 | 2.2% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $96.32 | 2.1% | 7 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $92.84 | 2.0% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $77.97 | 1.7% | 3 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $71.92 | 1.6% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $52.19 | 1.1% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $50.00 | 1.1% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $46.57 | 1.0% | 2 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $46.04 | 1.0% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $42.10 | 0.9% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $39.23 | 0.9% | 2 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $36.25 | 0.8% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $35.96 | 0.8% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $32.95 | 0.7% | 2 | 2025 |
| Fresenius Kabi USA, LLC | Unresolved — no canonical attribution shown | $31.56 | 0.7% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $30.79 | 0.7% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $30.73 | 0.7% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $22.84 | 0.5% | 1 | 2025 |
| Echosens North America, Inc. | Unresolved — no canonical attribution shown | $22.62 | 0.5% | 1 | 2025 |
| Braintree Laboratories, Inc. | Unresolved — no canonical attribution shown | $18.59 | 0.4% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $17.42 | 0.4% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.67 | 0.4% | 1 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $15.05 | 0.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $13.69 | 0.3% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $7.83 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,528.15 | 258 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $472.10 | 41 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $448.53 | 36 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $413.26 | 34 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $285.17 | 13 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $285.17 | 13 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $283.00 | 20 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $256.35 | 5 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $200.25 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $176.06 | 11 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $169.62 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $168.49 | 10 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $158.02 | 8 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $150.36 | 7 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $148.75 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $148.75 | 9 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $112.32 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $110.72 | 5 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $104.17 | 7 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $102.77 | 5 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $100.45 | 4 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $96.32 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $95.22 | 8 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $82.39 | 7 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $77.97 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $76.64 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $74.40 | 4 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $71.92 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $67.03 | 10 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $61.73 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $52.19 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $51.83 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $50.00 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $46.57 | 2 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $46.04 | 2 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $42.10 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $40.90 | 3 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $39.23 | 2 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $36.25 | 2 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $36.22 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $35.96 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $32.95 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $30.79 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $30.73 | 2 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $24.55 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $22.84 | 1 | 2025 |
Source payment records
|
|||||
| Fibroscan Normalized: fibroscan |
Device | Echosens North America, Inc. | $22.62 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.17 | 1 | 2025 |
Source payment records
|
|||||
| SUFLAVE Normalized: suflave |
Drug | Braintree Laboratories, Inc. | $18.59 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $17.42 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $16.67 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $15.45 | 1 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $15.05 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $13.69 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $13.69 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $12.73 | 2 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $7.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 198 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 48 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 585 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 197 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 61 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
75 | 23 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
43 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
48 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
198 | 45 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
365 | 364 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
93 | 80 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
585 | 87 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
197 | 38 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
198 | 45 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
61 | 60 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1563 | 455 |
| Levothyroxine Sodium | Levothyroxine Sodium | 756 | 204 |
| Amlodipine Besylate | Amlodipine Besylate | 728 | 225 |
| Atorvastatin Calcium | Atorvastatin Calcium | 689 | 227 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 634 | 192 |
| Mounjaro | Tirzepatide | 585 | 87 |
| Famotidine | Famotidine | 544 | 165 |
| Losartan Potassium | Losartan Potassium | 537 | 151 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 480 | 86 |
| Metformin Hcl | Metformin Hcl | 407 | 117 |
| Lisinopril | Lisinopril | 376 | 114 |
| Tramadol Hcl | Tramadol Hcl | 376 | 81 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 365 | 364 |
| Pantoprazole Sodium | Pantoprazole Sodium | 318 | 104 |
| Gabapentin | Gabapentin | 306 | 71 |
| Tamsulosin Hcl | Tamsulosin Hcl | 293 | 87 |
| Escitalopram Oxalate | Escitalopram Oxalate | 290 | 95 |
| Metoprolol Succinate | Metoprolol Succinate | 272 | 81 |
| Furosemide | Furosemide | 269 | 83 |
| Pregabalin | Pregabalin | 259 | 48 |
| Carvedilol | Carvedilol | 240 | 60 |
| Eszopiclone | Eszopiclone | 239 | 52 |
| Trazodone Hcl | Trazodone Hcl | 233 | 68 |
| Montelukast Sodium | Montelukast Sodium | 213 | 59 |
| Hydrochlorothiazide | Hydrochlorothiazide | 203 | 60 |
| Eliquis | Apixaban | 198 | 45 |
| Ozempic | Semaglutide | 197 | 38 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 191 | 149 |
| Bupropion Xl | Bupropion Hcl | 185 | 48 |
| Estradiol | Estradiol | 184 | 57 |
| Buspirone Hcl | Buspirone Hcl | 176 | 59 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 172 | 149 |
| Duloxetine Hcl | Duloxetine Hcl | 158 | 41 |
| Ezetimibe | Ezetimibe | 154 | 50 |
| Allopurinol | Allopurinol | 153 | 51 |
| Simvastatin | Simvastatin | 145 | 39 |
| Baclofen | Baclofen | 144 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 140 | 56 |
| Potassium Chloride | Potassium Chloride | 122 | 35 |
| Alprazolam | Alprazolam | 121 | 48 |
| Omeprazole | Omeprazole | 116 | 40 |
| Sod Sulf-Potass Sulf-Mag Sulf | Sodium, Potassium,mag Sulfates | 115 | 115 |
| Azithromycin | Azithromycin | 114 | 108 |
| Tizanidine Hcl | Tizanidine Hcl | 110 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 108 | 23 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 101 | 101 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 93 | 80 |
| Cefdinir | Cefdinir | 92 | 85 |
| Metformin Hcl Er | Metformin Hcl | 90 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 88 | 24 |
| Ibuprofen | Ibuprofen | 87 | 25 |
| Levofloxacin | Levofloxacin | 87 | 71 |
| Irbesartan | Irbesartan | 83 | 24 |
| Pioglitazone Hcl | Pioglitazone Hcl | 82 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 81 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 80 | 20 |
| Methylprednisolone | Methylprednisolone | 80 | 72 |
| Finasteride | Finasteride | 79 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 78 | 21 |
| Synthroid | Levothyroxine Sodium | 75 | 23 |
| Benazepril Hcl | Benazepril Hcl | 69 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 64 | 46 |
| Paxlovid | Nirmatrelvir/Ritonavir | 61 | 60 |
| Atenolol | Atenolol | 60 | 16 |
| Belsomra | Suvorexant | 59 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 59 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 58 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 56 | 16 |
| Valsartan | Valsartan | 56 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 53 | 12 |
| Lorazepam | Lorazepam | 51 | 14 |
| Spironolactone | Spironolactone | 51 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 50 | 12 |
| Farxiga | Dapagliflozin Propanediol | 48 | 12 |
| Ondansetron Odt | Ondansetron | 48 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 46 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 46 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 46 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 46 | 16 |
| Cephalexin | Cephalexin | 44 | 36 |
| Raloxifene Hcl | Raloxifene Hcl | 44 | 13 |
| Myrbetriq | Mirabegron | 43 | 14 |
| Sertraline Hcl | Sertraline Hcl | 43 | 12 |
| Meloxicam | Meloxicam | 42 | 12 |
| Progesterone | Progesterone, Micronized | 42 | 13 |
| Jardiance | Empagliflozin | 41 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 39 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 39 | suppressed |
| Ramipril | Ramipril | 39 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 39 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 38 | 29 |
| Prednisone | Prednisone | 38 | 15 |
| Promethazine Hcl | Promethazine Hcl | 38 | suppressed |
| Celecoxib | Celecoxib | 37 | 13 |
| Memantine Hcl | Memantine Hcl | 37 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 37 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Fluconazole | Fluconazole | 36 | 27 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 36 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | 19 |
| Valacyclovir | Valacyclovir Hcl | 35 | 20 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 34 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Colchicine | Colchicine | 33 | 17 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 33 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 17 |
| Repatha Sureclick | Evolocumab | 31 | suppressed |
| Testosterone | Testosterone | 31 | suppressed |
| Linzess | Linaclotide | 30 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 30 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Telmisartan | Telmisartan | 28 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Primidone | Primidone | 27 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 26 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 26 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Famciclovir | Famciclovir | 25 | 19 |
| Azelastine Hcl | Azelastine Hcl | 24 | 17 |
| Rizatriptan | Rizatriptan Benzoate | 24 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 24 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Clarithromycin | Clarithromycin | 23 | 22 |
| Zaleplon | Zaleplon | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 13 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Gemtesa | Vibegron | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Cilostazol | Cilostazol | 20 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 19 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Clonidine | Clonidine | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Tadalafil | Tadalafil | 17 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 17 | 11 |
| Topiramate | Topiramate | 17 | suppressed |
| Creon | Lipase/Protease/Amylase | 15 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Mesalamine | Mesalamine | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Dexamethasone | Dexamethasone | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 14 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Scopolamine | Scopolamine | 14 | 13 |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 13 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 13 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Bystolic | Nebivolol Hcl | 12 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 12 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | 11 |
| Dulera | Mometasone/Formoterol | 11 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
| Procto-Med Hc | Hydrocortisone | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,528.15 · 258 records | ABBVIE INC. | AIRSUPRA, Arikayce, Auvelity, CAMZYOS, CAPVAXIVE, COMIRNATY, CREON, CeQur Simplicity, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, FASENRA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, FREESTYLE LIBRE 3, Fibroscan, GARDASIL 9, GEMTESA, General - Pain Management, INJECTAFER, JARDIANCE, JOURNAVX, KISUNLA, Kerendia, Korlym, LINZESS, Leqembi, MOUNJARO, NEXLETOL, NURTEC ODT, OFEV, OTEZLA, Ozempic, PAXLOVID, PROCLAIM, PROLIA, QULIPTA, REPATHA, REXULTI, REZDIFFRA, Rybelsus, SUBLOCADE, SUFLAVE, Symbravo, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZENPEP, ZEPBOUND, t:slim X2 Insulin Pump with Control-IQ | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error